Table 3.
The effects of zacopride on the morphology of action potential (AP).
| N | RP (mV) | APA (mV) | APD50 (ms) | APD90 (ms) | |
|---|---|---|---|---|---|
| Control | 6 | –75.2 ± 0.8 | 105.8 ± 4.4 | 16.0 ± 3.3 | 30.1 ± 2.9 |
| Iso | 6 | –66.1 ± 3.2**# | 108.7 ± 4.6 | 101.3 ± 7.2**## | 127.0 ± 5.8**## |
| Iso+Zac | 6 | –73.1 ± 2.2 | 109.2 ± 3.7 | 35.6 ± 3.3* | 51.4 ± 3.4** |
| Iso+Zac+Chlo | 6 | –63.8 ± 2.2**## | 100.4 ± 3.1 | 66.1 ± 6.6**## | 92.3 ± 5.6**## |
APA, action potential amplitude; APD50 and APD90, action potential duration at 50% and 90% of repolarization, respectively; RP, resting potential; Iso, isoproterenol; Zac, zacopride; Chlo, chloroquine. *P < 0.05, **P < 0.01 vs. control; #P < 0.05, ##P < 0.01 vs. Iso+Zac.